Quetiapine Fumarate
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Quetiapine Fumarate是一种新型的非典型抗精神病药,用于治疗精神分裂症、双相性躁狂症、双相性II型抑郁症以及双相I型抑郁症[1]。Quetiapine的抗精神病作用可通过对多巴胺和5-羟色胺受体的拮抗活性介导。Quetiapine特异性拮抗D1和D2多巴胺、α1肾上腺素受体和α2肾上腺素受体以及5-HT1A和5-HT2血清素受体[1]。
体外实验:Quetiapine对各种神经递质受体具有亲和力,包括多巴胺、5-羟色胺、组胺和肾上腺素能受体,Quetiapine与多巴胺-2受体具有与clozapine相似的结合特性[1]。
在体实验:在动物模型中,Quetiapine表现出抗精神病活性的临床前效果,锥体外系症状(EPS)和持续的催乳素升高的倾向降低。Quetiapine改变神经降压素神经传递和c-fos在边缘而非运动脑区的表达。在人类中,Quetiapine表现出线性药代动力学,平均终末半衰期为7小时。Quetiapine的最佳剂量范围为150至750 mg/天,结果表明每日一次适用于部分患者[1]。Quetiapine以剂量依赖性方式阻止大鼠中由慢性约束应激(CRS)引起的海马细胞增殖和BDNF表达的抑制,预防精神分裂症。Guetiapine(5 mg/kg)与venlafaxine(2.5 mg/kg)共同使用增加海马细胞增殖,并阻止应激大鼠的BDNF减少,而每种药物单独使用发挥轻微效果或无效果[2]。在受到慢性约束应激的大鼠中,Quetiapine长期给药减轻了海马中脑源性神经营养因子(BDNF)水平的降低。在应激后给予quetiapine(10 mg/kg)7或21天后,逆转了应激诱导的海马神经发生的抑制, pCREB阳性和BrdU-标记细胞的数量与非应激大鼠中相当,但高于对照组处理的大鼠 [3]。
参考文献:
[1]. Nemeroff CB1, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry. 2002;63 Suppl 13:5-11.
[2]. Xu H1, Chen Z, He J, Haimanot S, Li X, Dyck L, Li XM. Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus. Hippocampus. 2006;16(6):551-9.
[3]. Luo C1, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res. 2005 Nov 23;1063(1):32-9. Epub 2005 Nov 4.
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 883.09 |
Cas No. | 111974-72-2 |
Formula | C46H54N6O8S2 |
Solubility | insoluble in H2O; insoluble in EtOH; ≥11.03 mg/mL in DMSO |
Chemical Name | 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol;(E)-but-2-enedioic acid |
SDF | Download SDF |
Canonical SMILES | C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=CC(=O)O)C(=O)O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
质量控制和MSDS
- 批次: